Alexion Pharmaceuticals
ALXN
ALXN was delisted on the 20th of July, 2021.
707 hedge funds and large institutions have $22.6B invested in Alexion Pharmaceuticals in 2020 Q3 according to their latest regulatory filings, with 75 funds opening new positions, 262 increasing their positions, 264 reducing their positions, and 70 closing their positions.
7% more first-time investments, than exits
New positions opened: 75 | Existing positions closed: 70
1% more capital invested
Capital invested by funds: $22.4B → $22.6B (+$224M)
0% more funds holding
Funds holding: 705 → 707 (+2)
1% less repeat investments, than reductions
Existing positions increased: 262 | Existing positions reduced: 264
13% less call options, than puts
Call options by funds: $275M | Put options by funds: $315M
14% less funds holding in top 10
Funds holding in top 10: 21 → 18 (-3)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$306M |
| 2 |
Janus Henderson Group
London,
United Kingdom
|
+$142M |
| 3 |
Man Group
London,
United Kingdom
|
+$89.1M |
| 4 |
AL
AJO LP
Philadelphia,
Pennsylvania
|
+$86.3M |
| 5 |
Nomura Holdings
Tokyo,
Japan
|
+$63.8M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$466M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
-$346M |
| 3 |
Ameriprise
Minneapolis,
Minnesota
|
-$101M |
| 4 |
CNBT
Cornerstone National Bank & Trust
Palatine,
Illinois
|
-$90.6M |
| 5 |
HM
HealthCor Management
New York
|
-$74.8M |
ALXN Hedge Fund Activity: Q3 2020 in Review
707 of the 4,956 institutional investors tracked by Wall St. Rank reported a position in Alexion Pharmaceuticals (ALXN) for Q3 2020, worth a combined $22.6B — up 1% from $22.4B a quarter earlier.
Buyers outnumbered sellers: 75 funds opened new ALXN positions and 70 closed out — a net gain of 5 holders — while 262 added to existing stakes and 264 trimmed.
The largest buyer was Vanguard Group, adding an estimated $306M. The largest seller was T. Rowe Price Associates, cutting an estimated $466M.
- 707 institutional investors held Alexion Pharmaceuticals (ALXN) as of Q3 2020, up from 705 in Q2 2020.
- Funds reported $22.6B of Alexion Pharmaceuticals stock for Q3 2020, up 1% quarter-over-quarter.
- 75 funds opened new Alexion Pharmaceuticals positions in Q3 2020 and 70 closed out, a net change of +5 holders.
- The largest Alexion Pharmaceuticals buyer in Q3 2020 was Vanguard Group, an estimated $306M added.
- The largest Alexion Pharmaceuticals seller in Q3 2020 was T. Rowe Price Associates, an estimated $466M sold.
Based on aggregated 13F filings for Q3 2020.